Heart disease as a risk factor for dementia

Clinical Epidemiology

Volumn 5, Issue 1, 2013, Pages 135-145

  Ng, Justin B ^a   Turek, Michele ^b,c   Hakim, Antoine M ^b,c,d,e  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e Canadian Stroke Network   (Canada)

Author keywords

Alzheimer's disease; Atrial fibrillation; Cardiovascular risk factors; Coronary artery disease; Heart failure; Myocardial infarction; Prevention; Valvular disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRENDIPINE; OMEGA 3 FATTY ACID; PLACEBO; TAU PROTEIN; WARFARIN;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN PERFUSION; BRAIN SIZE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; EXERCISE; FOOD INTAKE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; LIFESTYLE MODIFICATION; MEDITERRANEAN DIET; MULTIINFARCT DEMENTIA; OBESITY; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; VALVULAR HEART DISEASE;

EID: 84876976594     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S30621     Document Type: Review

References (173)

1. Ferri C P, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117.
2. United Nations, World Population Ageing 1950-2050, Population Division, DESA, United Nations, New York. ST/ESA/SER.A/207, 2002.
3. Mathers C, Leonard M. Global burden of dementia in the year 2000: summary of methods and data sources. Geneva: World Health Organization; 2000.
4. Ritchie K, Lovestone S. The dementias. Lancet. 2002;360(9347): 1759-1766.
5. Ganguli M, Snitz BE, Saxton JA, et al. Outcomes of mild cognitive impairment depend on defnition: a population study. Arch Neurol. 2011;68(6):761-767.
6. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007;68(19):1588-1595.
7. Hughes TF, Snitz BE, Ganguli M. Should mild cognitive impairment be subtyped? Current Opinion in Psychiatry. 2011;24(3):237-242.
8. Wolozin B, Bednar MM. Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res. 2006;28:630-636.
9. Paglieri C, Bisbocci D, Caserta M, et al. Hypertension and cognitive function. Clin Exp Hypertens. 2008;30(8):701-710.
10. Whitehouse PJ, Sciulli CG, Mason RM. Dementia drug development: use of information systems to harmonize global drug development. Psychopharmacol Bull. 1997;33(1):129-133.
11. Richard E, Ligthart SA, Moll van Charante EP, van Gool WA. Vascular risk factors and dementia-towards prevention strategies. Neth J Med. 2010;68(10):284-290.
12. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 1997;56:321-339.
13. Iemolo F, Duro G, Rizzo C, et al. Pathophysiology of vascular dementia. Immun Ageing. 2009;6:13.
14. Roman GC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc. 2003;51:S296-S304.
15. Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol. 2007;16:143-149.
16. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurolog y. 2005;65(4):545-551.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.
18. Kwon HM, Kim BJ, Lee SH, Choi SH, Oh BH, Yoon BW. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke. 2006;37(2):466-470.
19. Yaffe K. Metabolic syndrome and cognitive disorders: is the sum greater than its parts? Alzheimer Dis Assoc Disord. 2007;21:167-171.
20. Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA. 2004;292(23):2901-2908.
21. Bowler J, Hachinski V. Vascular dementia. In: Ginsberg M, Bogousslavsky J, editors. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. Oxford, UK: Science Ltd; 1998:1126-1144.
22. Reitz C, Brickman AM, et al. Frequency of subclinical heart disease in elderly persons with dementia. Am J Geriatr Cardiol. 2007; 16(3):183-188.
23. Jefferson AL, Himali JJ, Beiser AS, et al. Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation. 2010; 122(7):690-697.
24. Halling A, Berglund J. Association of diagnosis of ischaemic heart disease, diabetes mellitus and heart failure with cognitive function in the elderly population. Eur J Gen Pract. 2006;12:114-119.
25. Laughlin GA, McEvoy LK, von Mühlen D, et al. Sex differences in the association of Framingham Cardiac Risk Score with cognitive decline in community-dwelling elders without clinical heart disease. Psychosom Med. 2011;73(8):683-689.
26. Wolf PA. Contributions of the Framingham Heart Study to stroke and dementia epidemiologic research at 60 years. Arch Neurol. 2012; 69(5):567-571.
27. Watanabe M, Takeda T, Nakamagoe K, Tamaoka A. Sequential imaging analysis using MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve in Parkinson's disease. Eur J Neurol. 2011;18(7):1010-1013.
28. Newman A, Fitzpatrick A, Lopez O, et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc. 2005:53(7):1101-1107.
29. Roberts RO, Knopman DS, Geda YE, Cha RH, Roger VL, Petersen RC. Coronary heart disease is associated with non-amnestic mild cognitive impairment. Neurobiol Aging. 2010;31(11):1894-1902.
30. Rosengart TK, Sweet J, Finnin EB, et al. Neurocognitive functioning in patients undergoing coronary artery bypass graft surgery or perfuctaneous coronary intervention: evidence of impairment before intervention compared with normal controls. Ann Thorac Surg. 2005;80(4):1327-1334; discussion 1334-1335.
31. Freiheit EA, Hogan DB, Eliasziw M, et al. A dynamic view of depressive symptoms and neurocognitive change among patients with coronary artery disease. Arch Gen Psychiatry. 2012;69(3):244-255.
32. Koschack J, Irle E. Small hippocampal size in cognitively normal subjects with coronary artery disease. Neurobiol Aging. 2005;26:865-871.
33. Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C. Association of platelet activation with vascular cognitive impairment: implications in dementia development? Curr Vasc Pharmacol. Epub January 20, 2012.
34. Soneira CF, Scott TM. Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Clin Anat. 1996;9: 118-127.
35. Graban A, Bednarska-Makaruk M, Bochynska A, Lipczynska-Lojkowska W, Ryglewicz D, Wehr H. Vascular and biochemical risk factors of vascular dementia after lacunar strokes (S-VaD) and after multiinfarcts in strategic areas (M-VaD). J Neurol Sci. 2009;283(1-2):116-118.
36. Vidal JS, Sigurdsson S, Jonsdottir MK, et al. Coronary artery calcium, brain function and structure: the AGES-Reykjavik Study. Stroke. 2010;41:891-897.
37. Rosano C, Naydeck B, Kuller LH, et al. Coronary artery calcium: associations with brain magnetic resonance imaging abnormalities and cognitive status. J Am Geriatr Soc. 2005;53:609-615.
38. Kovacic JC, Castellano JM, Fuster V. The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. Ann N Y Acad Sci. 2012;1254:99-105.
39. Kovacic JC, Moreno P, Nabel EG, et al. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. Circulation. 2011;123:1900-1910.
40. Bell RD, Zlokovic B V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009;118: 103-113.
41. Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T. Cerebral amyloid angiopathy: a signifcant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci. 1993;116:135-141.
42. Kwok CS, Loke YK, Hale R, et al. Atrial fbrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76:914-922.
43. Tamam B, Taşdemir N, Tamam Y. The prevalence of dementia three months after stroke and its risk factors. Turk Psikiyatri Derg. 2008;19(1):46-56. Turkish.
44. Rastas S, Verkkoniemi A, Polvikoski T, et al. Atrial fbrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. Stroke. 2007;38:1454-1460.
45. Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T. Poststroke dementia: clinical features and risk factors. Stroke. 2000;31:1494-1501.
46. Zhou DH, Wang J Y, Li J, Deng J, Gao C, Chen M. Study on frequency and predictors of dementia after ischemic stroke: The Chongging Stroke study. J Neurol. 2004;251:421-427.
47. Marini C, Baldassarre M, Russo T, et al. A. Burden of frst-ever isch-emic stroke in the oldest old: evidence from a population-based study. Neurolog y. 2004;62:77-81.
48. Ratcliffe PJ, Wilcock GK. Cerebrovascular disease in dementia: the importance of atrial fbrillation. Postgrad Med J. 1985;61(713): 201-204.
49. O'Connell JE, Gray CS, French JM, et al. Atrial fibrillation and cognitive function: case-control study. J Neurol Neurosurg Psychiatry. 1998;65:386-389.
50. Sabatini T, Frisoni GB, Barbisoni P, et al. Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc. 2000;48:387-390.
51. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007;69: 1850-1858.
52. Bunch TJ, Weiss J P, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm. 2010;7:433-437.
53. Ott A, Breteler MM, de Bruyne MC, van HF, Grobbee DE, Hofman A. Atrial fbrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 1997;28(2):316-321.
54. Marzona I, O'Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patient with atrial fbrillation: results of the ONTARGET and TRANSCEND studies. CMAJ. 2012;184(6):E329-E336.
55. Miyasaka Y, Barnes ME, Petersen RC, et al. Risk of dementia in stroke-free patients diagnosed with atrial fbrillation: data from a community-based cohort. Eur Heart J. 2007;28:1962-1967.
56. Wozakowska-Kapłon B, Opolski G, Kosior D, Jaskulska-Niedziela E, Maroszyńska-Dmoch E, Włosowicz M. Cognitive disorders in elderly patients with permanent atrial fibrillation. Kardiol Pol. 2009;67:487-493.
57. Knecht S, Oelschlager C, Duning T, et al. Atrial fbrillation in stroke free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29:2125-2132.
58. Kermode-Scott B. Atrial fbrillation increases the risk of cognitive decline and need for long term care. BMJ. 2012;344:e1591.
59. Schrader J. The signifcance of arterial hypertension for the development of dementia. MMW Fortschr Med. 2004;146(47):40-42.
60. Petersen P, Kastrup J, Videbaek R, Boysen G. Cerebral blood fow before and after cardioversion of atrial fbrillation. J Cereb Blood Flow Metab. 1989;9:422-425.
61. Duron E, Hanon O. Atrial fbrillation and cognitive function. Psychol. Neuropsychiatr Vieil. 2010;8:209-214.
62. Morrison TB, Bunch TJ, Gersh BJ. Pathophysiology of concomitant atrial fbrillation and heart failure: implications for management. Nat Clin Pract Cardiovasc Med. 2009;6:46-56.
63. Ezekowitz MD, James KE, Nazarian SM, et al; for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Silent cerebral infarction in patients with nonrheumatic atrial fbrillation. Circulation. 1995;92(8):2178-2182.
64. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
65. Zito M, Muscari A, Marini E, Di Iorio A, Puddu GM, Abate G. Silent lacunar infarcts in elderly patients with chronic non valvular atrial fibrillation. Aging (Milano). 1996;8:341-346.
66. Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb. 2003;33:282-289.
67. Barber M, Tait RC, Scott J, Rumley A, Lowe GD, Stott DJ. Dementia in subjects with atrial fbrillation: hemostatic function and the role of anticoagulation. J Thromb Haemost. 2004;2:1873-1878.
68. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000;21:321-330.
69. Longstreth WT Jr, Manolio TA, Arnold A, et al. Clinical correlates of white matter fndings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke. 1996;27: 1274-1282.
70. Ikram MA, Hollander M, Bos MJ, et al. Unrecognized myocardial infarction and the risk of stroke: the Rotterdam Study. Neurology. 2006;67:1635-1639.
71. Zuccala G, Onder G, Pedone C, et al. Hypotension and cognitive impairment: selective association in patients with heart failure. Neurolog y. 2001;57:1986-1992.
72. Breteler MM, Claus JJ, Grobbee DE, et al. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ. 1994;308:1604-1608.
73. Aronson MK, Ooi WL, Morgenstern H, et al. Women, myocardial infarction, and dementia in the very old. Neurology. 1990;40:1102-1106.
74. Gharacholou SM, Reid KJ, Arnold S V, et al. Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: fnd-ings from the translational research investigating underlying disparities in acute myocardial infarction patients' health status registry. Am Heart J. 2011;162(5):860-869.
75. Ikram MA, Oijen M, Jong FJ, et al. Unrecognized myocardial infarction in relation to risk of dementia and cerebral small vessel disease. Stroke. 2008;39(5):1421-1426.
76. Grubb NR, Simpson C, Fox KA. Memory function in patients with stable, moderate to severe cardiac failure. Am Heart J. 2000;140:1-5.
77. Petrovitch H, White L, Masaki KH, et al. Infuence of myocardial infarction, coronary artery bypass surgery, and stroke on cognitive impairment in late life. Am J Cardiol. 1998;81:1017-1021.
78. Bursi F, Rocca WA, Killian JM, et al. Heart disease and dementia: a population-based study. Am J Epidemiol. 2006;163:135-141.
79. Corder E, Ervin J F, Lockhart E, Szymanski MH, Schmechel DE, Hulette CM. Cardiovascular damage in Alzheimer disease: autopsy fndings from the Bryan ADRC. J Biomed Biotechnol. 2005;2005(2):189-197.
80. Boudoulas KD, Sparks EA, Rittgers SE, Wooley CF, Boudoulas H. Factors determining left atrial kinetic energy in patients with chronic mitral valve disease. Herz. 2003;28:437-444.
81. Rodriguez CJ, Bartz TM, Lonstreth WT Jr, et al. Association of annular calcifcation and aortic valve sclerosis with brain fndings on magnetic resonance imaging in community dwelling older adults: the cardiovascular health study. J Am Coll Cardiol. 2011;57(21):2172-2180.
82. Oliveira-Filho J, Massaro AR, Yamamoto F, Bustamante L, Scaff M. Stroke as the first manifestation of calcifc aortic stenosis. Cerebrovasc Dis. 2000;10:413-416.
83. de la Torre JC. Cardiovascular risk factors promote brain hypoperfu-sion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol. 2012;2012:367516.
84. Belohlavek M, Jiamsripong P, Calleja AM, et al. Patients with Alzheimer disease have altered transmitral fow: echocardiographic analysis of the vortex formation time. J Ultrasound Med. 2009 Nov;28(11):1493-1500.
85. Giamouzis G, Triposkiadis F, Butler J, Westermann D, Giannakoulas G. Heart failure. Cardiol Res Pract. 2011;2011:159608.
86. Almeida, O P, Beer C, Lautenschlager NT, Arnolda L, Alfonso H, Flicker L. Two-year course of cognitive function and mood in adults with congestive heart failure and coronary artery disease: the Heart-Mind Study. Int Psychogeriatr. 2012;24(1):38-47.
87. Trojano L, Incalzi RA, Acanfora D, Picone C, Mecocci P, Rengo F. Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol. 2003;250(12):1456-1463.
88. Vogels RLC, Weinstein HC, Schroeder-Tanka JM. Cognitive impairment in heart failure: a systematic review of literature. Eur J Heart Fail. 2006;5(1):33-34.
89. Lavery L, Vander Bilt J, Chang CC, Saxton JA, Ganguli M. The association between congestive heart failure and cognitive performance in a primary care population of elderly adults: the Steel Valley Seniors Survey. Int Psychogeriatr. 2007;2:215-225.
90. Sauve MJ, Lewis WR, Blankenbiller M, Rickabaugh B, Pressler SJ. Cognitive impairments in chronic heart failure: a case controlled study. J Card Fail. 2009;15:1-10.
91. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006;166(9):1003-1008.
92. Polidori CM, Mariani E, Mecocci P. Congestive heart failure and Alzheimer's disease. Neurol Res. 2006;28(6):588-594.
93. Beer C, Ebenezer E, Fenner S, et al. Contributors to cognitive impairment in congestive heart failure: a pilot case-control study. Intern Med J. 2009;39(9):600-605.
94. Alves TC, Rays J, Fraguas R Jr, et al. Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc- HMPAO SPECT. J Neuroimaging. 2005;15:150-156.
95. Loncar G, Bozic B, Lepic T, et al. Relationship of reduced cerebral blood fow and heart failure severity in elderly males. Aging Male. 2011;14(1):59-65.
96. Gruhn N, Larsen FS, Boesgaard S, et al. Cerebral blood fow in patients with chronic heart failure before and after heart transplantation. Stroke. 2001;32(11):2530-2533.
97. Jefferson AL, Poppas A, Paul RH, Cohen RA. Systemic hypoperfusion is associated with executive dysfunction in geriatric cardiac patients. Neurobiol Aging. 2007;28(3):477-483.
98. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure. Physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747-1762.
99. Pullicino PM, Hart J. Cognitive impairment in congestive heart failure? Embolism vs hypoperfusion. Neurology. 2001;57(11):1945-1946.
100. Shprakh V V, Suvorova IA. Post-stroke vascular dementia: risk factors and clinical neuro-imaging features. Adv Gerontol. 2010;23(2):293-300.
101. Alonso A, Mosley TH Jr, Gottesman R F, et al. Risk of dementia hos-pitalization associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry. 2009;80:1194-1201.
102. Ettorre, E, Cerra E, Marigliano B. Role of cardiovascular risk factors (CRF) in the patients with mild cognitive impairment (MCI). Arch Gerontol Geriatr. 2012;54(2):330-332.
103. De Toledo Ferraz Alves TC, Scazufca M, Squarzoni P, et al. Subtle gray matter changes in temporo-parietal cortex associated witho cardiovascular risk factors. Journal of Alzheimer's Disease. 2011;27:575-589.
104. Schwartz E, Wicinski B, Schmeidler J, Haroutunian V, Hof PR. Cardiovascular risk factors affect hippocampal microvasculature in early AD. Transl Neurosci. 2010;1(4):292-299.
105. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res. 2006;28(6):605-611.
106. Weiner M, Rosenberg R, Womack K, et al. Atherosclerosis risk factors in American Indians with Alzheimer's disease: preliminary fndings. Alzheimer Dis Assoc Disord. 2008;22(3):245-248.
107. Mielke MM, Leoutsakos J-M, Tschanz JT. Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease. J Alzheimers Dis. 2011;26(1):127-134.
108. Jin Y P, Ostbye T, Feightner J W, Di Legge S, Hachinski V. Joint effect of stroke and APOE 4 on dementia risk: the Canadian Study of Health and Aging. Neurology. 2008;70:9-16.
109. Celle S, Annweiler C, Pichot V, et al. Association between ambulatory 24-hour blood pressure levels and brain volume reduction: a cross-sectional elderly population-based study. Hypertension. 2012; 60(5):1324-1331.
110. de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging. 2000;21:331-342.
111. Johnson KC, Margolis KL, Espeland MA, et al. A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study. J Am Geriatr Soc. 2008;56(8): 1449-1458.
112. Staessen JA, Richart T, Birkenhager WH. Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension. 2007;49:389-400.
113. Nagai M, Hoshide S, Kario K. Hypertension and dementia. Am J Hypertens. 2010;23:116-124.
114. Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc. 2003;51:410-414.
115. Shah NS, Vidal J-S, Masaki K, et al. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: The Honolulu Asia Aging Study. Hypertension. 2012;59(4):780-786.
116. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999;100:354-360.
117. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487-499.
118. Kalback W, Esh C, Castaño EM, et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res. 2004;26:525-539.
119. Hoffman LB, Schmeidler J, Lesser GT, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurolog y. 2009;72(20):1720-1726.
120. De Toledo Ferraz Alves TC, Ferreira LK, Wajngarten M, Busatto GF. Cardiac disorders as risk factors for Alzheimer's disease. J Alzheimers Dis. 2010;20(3):749-763.
121. Kennelly S P, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia-A double edged sword. Ageing Res Rev. 2009;8(2):61-70.
122. Nilsson SE, Read S, Berg S, Johansson B, Melander A, Lindblad U. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007;19:41-47.
123. Ott A, Stolk R P, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurolog y. 1999;53(9):1937-1942.
124. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51(4):1256-1262.
125. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004; 53(2):474-481.
126. Beeri MS, Ravona-Springer R, Silverman JM, Haroutunian V. The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci. 2009;11:201-212.
127. Schmidt R, Launer LJ, Nilsson LG, et al. CASCADE Consortium Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes. 2004;53(3):687-692.
128. Skoog I, Gustafson D. Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol Res. 2003;25(6):675-680.
129. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100(7):4162-4167.
130. Qiu WQ, Folstein M F. Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging. 2006;27(2):190-198.
131. Takeda S, Sato N, Rakugi H, Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid pep-tide, insulin signaling, and neuronal function. Mol Biosyst. 2011; 7(6):1822-1827.
132. Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech. 2012;5(6):746-755.
133. Robles Bayòn A, Gude Sampedro F. Inappropriate treatments for patients with cognitive decline. Neurologia. 2012;S0213-4853(12)00185-5.
134. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. 2007;166:367-378.
135. Kelly TN, Gu D, Chen J, et al. Cigarette smoking and risk of stroke in the Chinese adult population. Stroke. 2008;39:1688-1693.
136. Arntzen KA, Schirmer H, Wilsgaard T, Mathiesen EB. Impact of cardiovascular risk factors on cognitive function: the Tromsø study. Eur J Neurol. 2011;18:737-743.
137. De Toledo Ferraz Alves TC, Ferreira LK, Busatto GF. Vascular diseases and old age mental disorders: an update of neuroimaging fndings. Curr Opin Psychiatry. 2010;23(6):491-497.
138. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10(9):819-828.
139. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol. 2009;66:336-342.
140. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62(10):1556-1560.
141. Whitmer RA, Gunderson E P, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330(7504):1360.
142. Martins IJ, Hone E, Foster JK, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry. 2006; 11(8):721-736.
143. Pasinetti GM, Eberstein JA. Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J Neurochem. 2008;106:1503-1514.
144. Vercambre M-N, Grodstein F, Berr C, Kang JH. Mediterranean diet and cognitive decline in women with cardiovascular disease or risk factors. J Acad Nutr Diet. 2012;112(6):816-823.
145. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006;63(10):1402-1408.
146. Geleijnse JM, Giltay EJ, Kromhout D. Effects of N-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimers Dement. 2012; 8(4):278-287.
147. Levitan EB, Wolk A, Mittleman MA. Consistency with the DASH diet and incidence of heart failure. Arch Intern Med. 2009;169(9):851-857.
148. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol. 2009;66:216-225.
149. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol. 2006;59(6):912-921.
150. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neuro. 2006; 63(12):1709-1717.
151. Román GC, Nash DT, Fillit H. Translating current knowledge into dementia prevention. Alzheimer Dis Assoc Disord. 2012;26(4): 295-299.
152. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Annal Intern Med. 2006;144(2):73-81.
153. Aarsland D, Sardahaee FS, Anderssen S, Ballard C. Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health. 2010;14:386-395.
154. Vreugdenhil A, Cannell J, Davies A, Razay G. A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial. Scand J Caring Sci. 2012;26(1):12-19.
155. Khachaturian AS, Zandi P P, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686-692.
156. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci. 2005;229-230:151-155.
157. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-2052.
158. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-1075.
159. Guo Z, Fratiglioni L, Viitanen M, et al. Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication? Am J Epidemiol. 2001;153:225-231.
160. Launer LJ, Ross G W, Petrovitch H, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Brit Med J. 2001;322:1447-1451.
161. Igase M, Kohara K, Miki T. The Association between Hypertension and Dementia in the Elderly. Int J Hypertens. 2012;2012:320648.
162. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-689.
163. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev. 2006;2:CD004034.
164. Lee M, Saver JL, Chang B, Chang KH, Hao Q, Ovbiagele B. Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. Neurology. 2011;77(14):1330-1337.
165. Benavente OR, White CL, Pearce L, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke. 2011; 6(2):164-175.
166. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-128.
167. Wolozin B, Bednar MM. Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res. 2006;28:630-636.
168. Stanek KM, Gunstad J, Paul RH, et al. Longitudinal cognitive performance in older adults with cardiovascular disease: evidence for improvement in heart failure. J Cardiovasc Nurs. 2009;24(3):192-197.
169. Puccio D, Novo G, Baiamonte V, et al. Atrial fibrillation and mild cognitive impairment: what correlation? Minerva Cardioangiol. 2009;57:143-150.
170. Barber M, Tait RC, Scott J, Rumley A, Lowe GD, Stott DJ. Dementia in subjects with atrial fbrillation: hemostatic function and the role of anticoagulation. J Thromb Haemost. 2004;2(11):1873-1878.
171. Arikawa M, Kakinuma Y, Handa T, Yamasaki F, Sato T. Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice. PLoS One. 2011;6(7):e20629.
172. Handa T, Katare RG, Kakinuma Y, et al. Anti-Alzheimer's drug, Donepezil, markedly improves long-term survival after chronic heart failure in mice. J Card Fail. 2009;15(9): 805-811.
173. Sink KM, Leng X, Williamson J, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med. 2009; 169(13):1195-1202.